CytomX GAAP EPS of -$0.15 misses by $0.12, revenue of $76.2M misses by $6.69M

CytomX (CYTX) delivered a double-miss earnings print: GAAP EPS of -$0.15 versus consensus -$0.03 represents a 400% overshoot on the loss side, signaling materially elevated cash burn beyond street expectations. Revenue of $76.2M missing by $6.69M (~8.1% shortfall) implies collaboration milestones, licensing fees, or royalty streams failed to materialize on schedule — a structurally significant red flag for a pipeline-dependent biotech. The asymmetric EPS miss relative to revenue miss suggests operational cost escalation or one-time charges rather than pure top-line weakness, which complicates near-term cash runway modeling. Market will immediately reprice around updated burn rate trajectories, potential dilution risk via secondary offering, and revised partnership timelines — all net negative catalysts in the current tight biotech financing environment. ⚡ DEEP SONNET: Initiate short exposure on any opening bounce into prior support levels or VWAP rejection within first 30-60 minutes of trading; avoid chasing the initial gap-down open. Target entry zone on 2-5% dead-cat bounce from open. | TP:18% SL:9% | 3-7 trading days for primary move; reassess after earnings call management guidance | Risk:HIGH — Biotech-specific volatility creates extreme binary risk; any positive pipeline data point, FDA communication, or new partnership announcement can trigger violent reversal. Short interest dynamics in small-cap biotech can produce sharp short squeezes. Cash runway commentary in the earnings call is a wildcard that could either amplify or neutralize the bearish thesis entirely. | Sizing:CONSERVATIVE